Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — Corporate Update (August 2026)
23 slides from Jazz Pharmaceuticals's corporate update, Aug 25, 2026
Slide 1: Ziihera (zanidatamab-hrii) Launch Webcast
ZIIHERA ® (zanidatamab-hrii) Launch Webcast Innovating to Transform the Lives of Patients and Their Families Intended for U.S. investor audiences only. August 25, 2026
Slide 2: Caution Concerning Forward-Looking Statements
Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to: the company’s advancement of pipeline programs and the timing of development activities, regulatory
Slide 3: Agenda
Agenda Introduction and Overview John Bluth Head of Investor Relations Ziihera: Clinical Overview Robert Iannone, M.D., M.S.C.E. Chief Medical Officer and Global Head of Research and Development Ziihera: GEA Commercial Overview Chumi Khurana Oncology Franchise Head Ziihera: Beyond GEA Samantha Pearc
Slide 4: Introduction and Overview
Introduction and Overview John Bluth Head of Investor Relations Intended for U.S. investor audiences only. 4
Slide 5: Now Commercially Available
Now Commercially Available • First and only bispecific HER2-targeted antibody combined with a PD-1 inhibitor and chemotherapy approved for all HER2+ advanced GEA patients, regardless of PD-L1 status, establishing a new standard of care in first-line treatment • Ziihera combinations exceeded two year
Slide 6: Clinical Overview
Clinical Overview Robert Iannone, M.D., M.S.C.E. Executive Vice President, Global Head of Research and Development and Chief Medical Officer Intended for U.S. investor audiences only. 6
Slide 7: Ziihera U.S. Label
Ziihera U.S. Label Highlights of prescribing information Indications and Indicated for GEA: • In combination with fluoropyrimidine- and platinum-containing chemotherapy, and tislelizumab-jsgr, as first-line Usage treatment of adult patients with HER2-positive (IHC 3+ and IHC 2+/ISH+) unresectable lo
Slide 8: Ziihera plus Tislelizumab and Chemo Show Superior Overall Survival
Ziihera plus Tislelizumab and Chemo Show Superior Overall Survival Data summary from USPI comparing Arm C and Arm A in patients with HER2 IHC 3+ and IHC 2+/ISH+ Arm C Arm A Efficacy Parameter Ziihera with chemotherapy and tislelizumab Trastuzumab with chemotherapy N=302 N=308 Overall Survival Median
Slide 9: Ziihera and Chemo Show Superior Overall Survival
Ziihera and Chemo Show Superior Overall Survival Data Summary from USPI comparing Arm B and Arm A in patients with HER2 IHC 3+ Arm B Arm A Efficacy Parameter Ziihera with chemotherapy Trastuzumab with chemotherapy N=251 N=255 Overall Survival Median, months (95% CI) 25.5 (21.9, 30.3) 19.8 (16.2, 22.
Slide 10: Ziihera U.S. Label: Warnings and Boxed Warning
Ziihera U.S. Label Highlights of prescribing information Warnings and Boxed Warning for Diarrhea and Embryo-Fetal Toxicity • ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr, Precautions can cause severe diarrhea, including life th
Slide 11: Zanidatamab's Biparatopic Binding Drives Unique MOA and Clinical Activity
Zanidatamab’s Biparatopic Binding Drives Unique MOA and Clinical Activity Zanidatamab simultaneously binds two non-overlapping extracellular domains of HER2 (biparatopic binding) Unique geometry and binding properties result in multiple mechanisms of action ADCC / ADCP = antibody-dependent cellular
Slide 12: GEA Commercial Overview
GEA Commercial Overview Chumi Khurana Senior Vice President, Oncology Franchise Head Intended for U.S. investor audiences only. 12
Slide 13: Unmet Need Remains In Gastroesophageal Adenocarcinoma (GEA)
Unmet Need Remains In Gastroesophageal Adenocarcinoma (GEA) ANATOMIC LOCATION OF GEA1–2 DISEASE OVERVIEW1-8 ~8K ~3-4K <10% 14-20 Esophagus months GEJ HER2+ GEA Ziihera treatable patient Five-year survival Median patient population population rate in mGEA overall survival Symptoms Pylorus Stomach Bod
Slide 14: New Standard of Care in 1L HER2+ GEA
New Standard of Care in 1L HER2+ GEA 1 Ziihera = New Standard of Care for 1L HER2+ mGEA Regardless of PD-L1 Status PRIOR STANDARD OF CARE NEW STANDARD OF CARE Advanced Advanced HER2+ GEA HER2+ GEA PD-L1+ PD-L1- PD-L1+ PD-L1- (CPS ≥1) (CPS <1) (CPS ≥1) (CPS <1) Trastuzumab + ZIIHERA + tislelizumab +
Slide 15: Ready for GEA Launch
Ready for GEA Launch Goal: Establish Ziihera as HER2-Targeted Agent of Choice in 1L HER2+ GEA 1. Clinical Education & Differentiation 2. Accelerated Market Access Establishing the new Standard of Care: Ziihera + tislelizumab Leveraging immediate reimbursement: Utilize established, as foundational ba
Slide 16: Strategic Investment in Educating Nurses & Patients Will Accelerate GEA Adoption
Strategic Investment in Educating Nurses & Patients Will Accelerate GEA Adoption and Adherence, Helping Patients Start and Stay on Ziihera Objectives Patient Education Resources Nurse Education Resources Clinical Educator Team • Dosing & Administration Guide • NEW for GEA Launch: Oncology • Patient
Slide 17: Beyond GEA
Beyond GEA Samantha Pearce Executive Vice President, Chief Commercial Officer Intended for U.S. investor audiences only. 17
Slide 18: Robust Ongoing Zanidatamab Development Program
Robust Ongoing Zanidatamab Development Program PHASE 1 PHASE 2 PHASE 3 RECENT / UPCOMING MILESTONES 1L GEA (HERIZON-GEA-01) Now Approved 1L BTC (HERIZON-BTC-302) 1L BTC confirmatory trial Metastatic breast cancer (mBC) patients post T-DXd (EmpowHER-BC-303) Anticipate top-line data late 2027 / early
Slide 19: Zanidatamab: Updated Peak Sales Opportunity of $3-$5B
Zanidatamab: Updated Peak Sales Opportunity of $3-$5B Drivers of Peak Sales Increase: • Approvals in BTC and GEA, derisked investments in existing studies • Additional registrational trials planned in CRC, NSCLC, and early gastric cancer Other HER2- • Additional registrational opportunities in mBC,
Slide 20: Closing Remarks
Closing Remarks Intended for U.S. investor audiences only. 20
Slide 21: Ziihera Poised for Significant Growth
Ziihera Poised for Significant Growth 2026 2027 and Beyond Commercial Launch Robust Development Program • GEA launched on 25 August 2026 • Initiate CRC and NSCLC Phase 3 trials • Product available for supply to treatment • Continue to broaden development program centers/physicians in Breast Cancer •
Slide 22: Q&A
Q&A Intended for U.S. investor audiences only. 22
Slide 23: Thank You
Thank You … to the numerous patients and their families who participated in our clinical development program. … to the clinical investigators, physicians, nurses, site coordinators, and countless support staff. … to the Jazz and BeOne teams continuously working to deliver this important medicine to
Jazz Pharmaceuticals — Corporate Update (August 2026) on 6ix